MYRIAD GENETICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
MYRIAD GENETICS, INC. (MYGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $400.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2025-02-28
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-12-31 was -$100.00K.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-06-30 was $700.00K.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2024-03-31 was -$200.00K.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $400.00K.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2023 was -$1.50M.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2022 was -$400.00K.
- MYRIAD GENETICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$100.00K derived: sum of 2 quarters · filed 2025-02-28 | $600.00K derived: sum of 3 quarters · filed 2025-02-28 | $400.00K 10-K · filed 2025-02-28 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $700.00K derived: sum of 2 quarters · filed 2024-11-08 | $500.00K 10-Q · filed 2024-11-08 | -$2.60M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2024-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $500.00K 10-Q · filed 2024-08-07 | -$2.60M derived: sum of 3 quarters · filed 2025-02-28 | -$200.00K derived: sum of 4 quarters · filed 2025-02-28 | |
| 2024-03-31 | -$200.00K 10-Q · filed 2024-05-08 | -$3.30M derived: sum of 2 quarters · filed 2025-02-28 | -$900.00K derived: sum of 3 quarters · filed 2025-02-28 | ||
| 2023-12-31 | -$3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$700.00K derived: sum of 2 quarters · filed 2025-02-28 | -$1.50M 10-K · filed 2025-02-28 | $0.00 10-K · filed 2024-02-28 | |
| 2023-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.60M 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | -$800.00K 10-Q · filed 2023-08-04 | ||||
| 2022-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$900.00K derived: sum of 2 quarters · filed 2025-02-28 | -$900.00K derived: sum of 3 quarters · filed 2025-02-28 | -$400.00K 10-K · filed 2025-02-28 | $400.00K 10-K · filed 2023-03-01 |
| 2022-09-30 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$300.00K derived: sum of 2 quarters · filed 2022-11-02 | $200.00K 10-Q · filed 2022-11-02 | $1.90M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $500.00K 10-Q · filed 2022-08-05 | $2.20M derived: sum of 3 quarters · filed 2024-02-28 | $1.80M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $500.00K 10-Q · filed 2022-05-06 | $2.20M derived: sum of 2 quarters · filed 2024-02-28 | $1.80M derived: sum of 3 quarters · filed 2024-02-28 | $1.40M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.30M derived: sum of 2 quarters · filed 2024-02-28 | $900.00K derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | -$1.80M 10-K · filed 2022-02-25 |
| 2021-09-30 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$800.00K derived: sum of 2 quarters · filed 2021-11-04 | -$1.70M 10-Q · filed 2021-11-04 | -$6.30M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$1.30M 10-Q · filed 2021-08-04 | -$5.90M derived: sum of 3 quarters · filed 2023-03-01 | -$4.80M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-03-31 | -$900.00K 10-Q · filed 2021-05-05 | -$5.50M derived: sum of 2 quarters · filed 2023-03-01 | -$4.40M derived: sum of 3 quarters · filed 2023-03-01 | $1.20M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-12-31 | -$4.60M derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | -$3.50M 10-K · filed 2023-03-01 | $2.10M derived: sum of 3 quarters · filed 2023-03-01 | -$1.30M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-09-30 | $1.10M 10-Q · filed 2020-11-09 | $6.70M derived: sum of 2 quarters · filed 2023-03-01 | $3.30M derived: sum of 3 quarters · filed 2023-03-01 | $4.60M derived: sum of 4 quarters · filed 2023-03-01 | |
| 2020-06-30 | $5.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $2.20M derived: sum of 2 quarters · filed 2023-03-01 | $3.50M derived: sum of 3 quarters · filed 2023-03-01 | $2.80M 10-K · filed 2023-03-01 | -$2.80M 10-K · filed 2020-08-13 |
| 2020-03-31 | -$3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-06 | -$2.10M derived: sum of 2 quarters · filed 2020-05-06 | -$2.80M 10-Q · filed 2020-05-06 | -$3.10M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | $600.00K 10-Q · filed 2020-02-07 | $300.00K derived: sum of 3 quarters · filed 2022-02-25 | $300.00K derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-09-30 | -$700.00K 10-Q · filed 2019-11-06 | -$1.00M derived: sum of 2 quarters · filed 2022-02-25 | -$1.00M derived: sum of 3 quarters · filed 2022-02-25 | $0.00 derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-06-30 | -$300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$300.00K derived: sum of 2 quarters · filed 2022-02-25 | $700.00K derived: sum of 3 quarters · filed 2022-02-25 | $1.10M 10-K · filed 2022-02-25 | -$1.10M 10-K · filed 2019-08-13 |
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-08 | $1.00M derived: sum of 2 quarters · filed 2019-05-08 | $1.40M 10-Q · filed 2019-05-08 | $1.50M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2018-12-31 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-06 | $1.40M 10-Q · filed 2019-02-06 | $1.50M derived: sum of 3 quarters · filed 2019-02-06 | $400.00K derived: sum of 4 quarters · filed 2019-02-06 | |
| 2018-09-30 | $400.00K 10-Q · filed 2018-11-07 | $500.00K derived: sum of 2 quarters · filed 2018-11-07 | -$600.00K derived: sum of 3 quarters · filed 2018-11-07 | $12.40M derived: sum of 4 quarters · filed 2018-11-07 | |
| 2018-06-30 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-24 | -$1.00M derived: sum of 2 quarters · filed 2018-08-24 | $12.00M derived: sum of 3 quarters · filed 2018-08-24 | -$61.20M 10-K · filed 2018-08-24 | |
| 2018-03-31 | -$1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09 | $11.90M derived: sum of 2 quarters · filed 2018-05-09 | -$61.30M 10-Q · filed 2018-05-09 | -$64.00M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-07 | -$60.20M 10-Q · filed 2018-02-07 | -$62.90M derived: sum of 3 quarters · filed 2018-02-07 | -$57.70M derived: sum of 4 quarters · filed 2018-02-07 | |
| 2017-09-30 | -$73.20M 10-Q · filed 2017-11-08 | -$75.90M derived: sum of 2 quarters · filed 2017-11-08 | -$70.70M derived: sum of 3 quarters · filed 2017-11-08 | -$74.50M derived: sum of 4 quarters · filed 2017-11-08 | |
| 2017-06-30 | -$2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-09 | $2.50M derived: sum of 2 quarters · filed 2017-08-09 | -$1.30M derived: sum of 3 quarters · filed 2017-08-09 | -$800.00K 10-K · filed 2017-08-09 | |
| 2017-03-31 | $5.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-03 | $1.40M derived: sum of 2 quarters · filed 2017-05-03 | $1.90M 10-Q · filed 2017-05-03 | ||
| 2016-12-31 | -$3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-08 | -$3.30M 10-Q · filed 2017-02-08 | |||
| 2016-09-30 | $500.00K 10-Q · filed 2016-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |